CAR-T Therapy Hospitals in China 2026: Top 10 Centers for International Patients

What Is CAR-T Therapy and Why China?

CAR-T (Chimeric Antigen Receptor T-cell) therapy is a form of immunotherapy that reprograms a patient's own T-cells to recognize and attack cancer. A patient's T-cells are collected, genetically engineered in a lab to carry a receptor that targets cancer cells, then infused back into the patient after a short chemotherapy conditioning regimen.

China became the world's largest CAR-T market by volume in 2024. The country's National Medical Products Administration (NMPA) has approved seven CAR-T products, compared to six FDA-approved products in the United States. Beyond the approved therapies, China runs more active CAR-T clinical trials than any other country — including trials for solid tumors that are not yet treatable with CAR-T elsewhere.

For international patients, the appeal is straightforward: access to experienced centers, significantly lower costs, and the ability to combine treatment with follow-up care or tourism. The main CAR-T treatment cost in China ranges from $89,000 to $151,000, compared to $500,000 to $699,000 in the United States.

Top 10 CAR-T Therapy Hospitals in China for International Patients

CAR-T Therapy Cost Comparison: China vs. United States vs. Other Destinations

Cost is a major driver for international patients considering CAR-T therapy abroad. The table below compares treatment costs at major destinations as of 2026.

Country / Hospital	Estimated CAR-T Cost (USD)	Insurance / Direct Billing	English-Speaking Staff
China (Public Hospital, e.g., Ruijin, PUMCH)	$80,000–$151,000	Limited; self-pay primary	Yes, at international centers
China (Private Hospital, e.g., SinoUnited)	$130,000–$165,000	Some international insurers accepted	Yes — international model
United States (MSK, MD Anderson, etc.)	$500,000–$699,000	Medicare, some private insurers	Yes
United Kingdom (NHS via CDF)	Covered for eligible patients	NHS / Cancer Drugs Fund	Yes
Germany (University hospitals)	$400,000–$600,000	Public or private insurance	Yes
India (with international programs)	$50,000–$90,000	Self-pay primarily	Yes
Japan (limited CAR-T centers)	$300,000–$450,000	National Health Insurance (residents)	Limited

How International Patients Access CAR-T Therapy in China: Step by Step

Step 1: Remote Evaluation (1-3 days)

Before traveling, most hospitals offer a remote consultation. You will need to provide your medical records: pathology reports, prior treatment history, current PET-CT or bone marrow biopsy results in English. The hospital's CAR-T team will review your case and confirm whether you are a candidate. This consultation is typically free or low-cost.

Step 2: Visa and Travel Arrangements (1-2 weeks)

Once you confirm treatment, the hospital issues a medical visa invitation letter (M-visa, valid for up to 6 months with extensions available). You will need to book flights to the city where your chosen hospital is located. Beijing (PEK/PKX), Shanghai (PVG), and Guangzhou (CAN) all have direct international flights from major global hubs.

Step 3: T-Cell Collection (Days 1-2)

Upon arrival at the hospital, you will undergo leukapheresis, a procedure similar to dialysis where blood is drawn, T-cells are separated out, and the rest of the blood is returned to your body. The procedure takes 3-5 hours and does not require general anesthesia. Most patients feel tired afterward but resume normal activities within 24 hours.

Step 4: Cell Processing (10-14 days)

Your collected T-cells are sent to the hospital's GMP-certified cell processing laboratory where they are genetically engineered to carry the CAR receptor. During this period, you may be asked to stay locally (the hospital can recommend partner hotels) and may receive bridging chemotherapy to keep your cancer under control while waiting.

Step 5: Conditioning Chemotherapy (3-5 days)

Before the CAR-T infusion, you will receive a short course of chemotherapy (typically fludarabine and cyclophosphamide over 3-5 days). This conditioning regimen suppresses your immune system so your body does not reject the engineered cells. Side effects include fatigue and lowered blood counts, manageable in the hospital setting.

Step 6: CAR-T Infusion (Day 1)

The engineered CAR-T cells are infused back into your body through an IV line (a 30-minute procedure). You will be monitored closely for the first few hours. Most patients stay in the hospital for 2-3 weeks after infusion for monitoring and management of potential side effects.

Step 7: Monitoring and Discharge (2-4 weeks)

The primary risk after CAR-T infusion is cytokine release syndrome (CRS), a systemic inflammatory response that can cause fever, low blood pressure, and in severe cases organ dysfunction. Chinese CAR-T centers have extensive experience managing CRS with targeted IL-6 inhibitors (tocilizumab). Once your care team confirms your CRS is under control and your blood counts are recovering, you will be discharged with a follow-up schedule.

Step 8: Follow-Up Care

After leaving the hospital, you will need regular blood tests and PET-CT scans to monitor your response. Most international patients arrange for follow-up scans at their home hospital and share results with their Chinese CAR-T team via email or telemedicine follow-up appointments. Your Chinese hospital can provide a complete treatment summary in English for your home oncologist.

CAR-T Therapy for Solid Tumors: What Is Available in China

Most commercially approved CAR-T therapies treat blood cancers. However, China leads the world in solid tumor CAR-T trials, where immune cells are engineered to target solid tumors that form masses in organs.

What Cancers Does CAR-T Treat? Approved and Trial-stage Therapies in China

The table below summarizes commercially approved CAR-T indications in China and active trial programs relevant to international patients.

Cancer Type	CAR-T Target	NMPA Approved (China)	US FDA Approved	China Trial Available
B-cell acute lymphoblastic leukemia (ALL) — adult & pediatric	CD19	Yes	Yes	Yes (extended indications)
Diffuse large B-cell lymphoma (DLBCL)	CD19	Yes	Yes	Yes
Follicular lymphoma (FL)	CD19	Yes	Yes	Yes
Mantle cell lymphoma (MCL)	CD19	Yes	Yes	Yes
Multiple myeloma	BCMA	Yes	Yes	Yes (next-generation products)
Liver cancer (hepatocellular carcinoma)	GPC3	Trial only	Trial only	Yes — SYSUCC, Fudan
Gastric / pancreatic cancer	Claudin18.2	Trial only	Trial only	Yes — Fudan Cancer Hospital
Systemic lupus erythematosus (SLE)	CD19	Trial only	Trial only	Yes — Ruijin, West China Hospital

Real Patient Stories: CAR-T Therapy in China

"I was told by my oncologist in the UK that CAR-T was available on the NHS but only after two prior lines of treatment had failed. By that point, my lymphoma was progressing quickly. Fudan Cancer Hospital had a CAR-T slot available within two weeks. The international patient team arranged everything — the visa letter, the hotel near the hospital, even a Cantonese-speaking interpreter for my consultations. The total cost was about £90,000 less than the private UK quote I had received. Three months after the infusion, my PET scan showed complete metabolic response."

— Patient from the United Kingdom, treated at Fudan Cancer Hospital, 2025

"My mother had relapsed acute lymphoblastic leukemia and needed CAR-T quickly. We consulted with hospitals in the US and Germany but the earliest slots were 8-10 weeks out. Peking Union Medical College Hospital could admit her within 12 days. The care team was professional, the ward was modern, and the doctors communicated with her home oncologist in Singapore throughout the process. She is now 18 months post-CAR-T with no evidence of disease."

— Patient family from Singapore, treated at PUMCH, 2024

How to Choose the Right CAR-T Hospital in China

Choosing a CAR-T hospital involves weighing several factors that vary by patient situation. Here is a practical decision framework based on the most common international patient profiles.

For blood cancer patients (lymphoma, leukemia, multiple myeloma)

Ruijin Hospital, Fudan Cancer Hospital, and PUMCH are the most established programs with the longest published outcome datasets. If you have relapsed after prior treatment and need CAR-T quickly, Fudan and Ruijin typically have the shortest wait times. If you have specific insurance requirements or need direct billing support, SinoUnited Hospital is the most internationally integrated option, though at a higher price point.

For solid tumor patients (liver, gastric, pancreatic cancer)

Fudan Cancer Hospital and SYSUCC are the only centers with active solid tumor CAR-T programs that have treated international patients. Fudan's Claudin18.2 program for gastric cancer is the most advanced globally. SYSUCC's GPC3 program for liver cancer has the longest follow-up data. Enrollment in a clinical trial requires careful screening and is not guaranteed.

For autoimmune disease patients (SLE, multiple sclerosis)

Ruijin Hospital and West China Hospital have the most active autoimmune CAR-T programs. These are still clinical trials — eligibility is restricted to patients meeting specific disease activity criteria. The potential benefit is that a single CAR-T infusion may produce sustained remission lasting years, potentially replacing ongoing immunosuppressive drug therapy.

For budget-conscious patients

Public Tier 3A hospitals offer CAR-T at $80,000-$130,000. Wuhan Union Hospital and Zhejiang Cancer Hospital tend to be at the lower end of the range. The trade-off is less English-language support and a more traditional hospital environment. Private international hospitals like SinoUnited charge $130,000-$165,000 but offer Western-style care, English-speaking physicians, and international insurance billing.

CAR-T Therapy Side Effects: What to Expect

Understanding CAR-T side effects is critical for any patient considering this treatment. Chinese CAR-T centers have managed thousands of cases and are experienced in handling these complications.

Cytokine Release Syndrome (CRS)

CRS is the most common side effect, occurring in 50-90% of patients depending on the CAR-T product and cancer type. It is caused by the immune system's reaction to the engineered cells. Symptoms include high fever, chills, low blood pressure, rapid heartbeat, and fatigue. In severe cases (Grade 3-4 CRS, occurring in 10-20% of patients), it can cause organ stress that requires ICU-level care. Chinese hospitals treat CRS with tocilizumab (an IL-6 receptor blocker) and steroids, following international guidelines.

Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)

ICANS affects the nervous system and can cause confusion, difficulty speaking, tremors, seizures, or altered consciousness. It typically occurs within the first week after infusion and is managed with steroids and, in severe cases, siltuximab. Chinese centers have ICANS management protocols that mirror those used at major US cancer centers.

Prolonged Low Blood Counts

After conditioning chemotherapy and CAR-T infusion, most patients experience low white blood cell, red blood cell, and platelet counts for several weeks. During this period, patients are at increased risk of infection and may require growth factor injections and platelet transfusions. Most hospitals keep patients hospitalized during this critical period.

On-Target, Off-Tumor Effects

Because some CAR-T products target proteins that also appear on healthy cells (e.g., CD19 on normal B-cells), patients may experience long-term depletion of normal B-cells, requiring immunoglobulin replacement therapy. This is manageable but requires ongoing monitoring.

Frequently Asked Questions

Which hospitals in China offer CAR-T therapy for international patients?

Top hospitals offering CAR-T therapy to international patients include Peking Union Medical College Hospital (Beijing), Fudan Cancer Hospital (Shanghai), Shanghai Ruijin Hospital, Lu Daopei Hospital (Beijing), Peking University People's Hospital, and SinoUnited Hospital (Shanghai). These hospitals have dedicated international patient departments and English-speaking staff.

How much does CAR-T therapy cost at hospitals in China?

CAR-T therapy in China costs between $89,000 and $151,000 depending on the hospital and whether the patient needs bridging chemotherapy. This is 65-80% less than the $500,000-$699,000 cost in the United States. Private international hospitals in China charge $130,000-$165,000 but offer Western-style care and international insurance billing.

How long does CAR-T treatment take at Chinese hospitals?

The full CAR-T treatment process takes 4-6 weeks on-site at the hospital. This includes T-cell collection (1-2 days), cell processing (10-14 days), bridging chemotherapy if needed, a short chemotherapy conditioning cycle, and the CAR-T infusion itself followed by 2-3 weeks of monitoring.

Does insurance cover CAR-T therapy at Chinese hospitals for international patients?

Most international insurance plans do not automatically cover treatment at hospitals outside the patient's home country. International patients should confirm coverage with their insurer before traveling. Some hospitals, particularly SinoUnited Hospital, offer direct billing assistance with international insurance providers.

What cancers does CAR-T therapy treat at Chinese hospitals?

CAR-T therapy in China is approved for B-cell acute lymphoblastic leukemia (ALL), relapsed or refractory large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and multiple myeloma. China is also leading in solid tumor CAR-T trials targeting GPC3 (liver cancer) and Claudin18.2 (gastric cancer) at centers like Fudan Cancer Hospital and SYSUCC.

Can international patients access CAR-T clinical trials in China?

Yes. Several Chinese hospitals offer CAR-T clinical trials to international patients, particularly for solid tumors (liver, gastric, pancreatic cancer) and autoimmune diseases (SLE, multiple sclerosis). Trial participation requires meeting eligibility criteria and traveling for screening before treatment. Trial participation may reduce or eliminate CAR-T product costs.

How do I prepare medical records for a Chinese CAR-T hospital?

Prepare the following in English: pathology reports confirming your diagnosis, prior treatment history (chemotherapy regimens, radiation, surgery), most recent PET-CT or bone marrow biopsy results, any prior CAR-T or transplant records if applicable, and a summary letter from your current oncologist. Most hospitals offer free remote case review before you commit to travel.

Ready to Explore CAR-T Treatment in China?

Getting accurate information about your specific case is the first step. Our team can help you identify the most suitable CAR-T hospital based on your diagnosis, treatment history, and budget — and provide a free case review from our medical coordinators.

Related Articles

• CAR-T Cell Therapy Cost in China 2026: $89,000–$151,000 vs $500,000+ in the US
• Cancer Treatment Cost in China 2026: Complete Price Guide
• Best Cancer Hospitals in China for International Patients 2026
• Brain Tumor Surgery in China 2026: Costs, Top Surgeons & Treatment Options